A Phase 3 interventional study of Vonaprument and Sham Administration in Geographic Atrophy, sponsored by Annexon, Inc.. Active, not recruiting at 132 sites in 14 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Annexon, Inc. · Phase 3, Interventional, and Treatment
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
This study's enrollment of 659 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Browse Geographic Atrophy studies →Annexon, Inc. is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTE: Other protocol-defined inclusion and exclusion criteria apply.
Participants will receive vonaprument IVT injections every month during the 24-month treatment period.
Drug: Vonaprument
Participants will receive Sham IVT injections every month during the 24-month treatment period.
Other: Sham Administration
Form: solution for injection; Route of Administration: IVT injection
Also known as: ANX007
Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).
Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits
Time frame: Baseline through Month 15
Proportion of Participants Experiencing a BCVA ≥15-letter Loss from Baseline Through Month 24 as Assessed by the ETDRS Chart at Any Two Consecutive Visits
Time frame: Baseline through Month 24
Time to Confirmed BCVA ≥15-letter Loss
Time frame: Baseline to Month 15 and Baseline to Month 24
Proportion of Participants with Low-luminance BCVA (LLVA) ≥15-letter Loss
Time frame: Baseline through Month 15 and Baseline through Month 24
Change from Baseline in Area of Total Loss of the Ellipsoid Zone (EZ) Layer
Time frame: Baseline, Month 15 and 24
Showing the first 100 of 132 sites across 14 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonaprument
Annexon, Inc.